Market-Moving News for June 18th
$ASNS
$ITCI
$LZB
Telecommunications Equipment
Telecommunications
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ASNS alert in real time by email
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/6/2024 | $68.00 → $92.00 | Neutral → Overweight | Piper Sandler | |
| 8/21/2024 | $43.00 | Buy → Neutral | Sidoti | |
| 1/3/2024 | $83.00 | Outperform | Robert W. Baird | |
| 12/11/2023 | $75.00 | Outperform | TD Cowen | |
| 4/20/2023 | $80.00 | Overweight | Morgan Stanley | |
| 8/25/2022 | Outperform → Mkt Perform | Raymond James | ||
| 8/22/2022 | $64.00 → $49.00 | Buy → Neutral | Goldman | |
| 7/7/2022 | $74.00 | Buy | Mizuho |
MONROE, Mich., Sept. 16, 2024 (GLOBE NEWSWIRE) -- La-Z-Boy Incorporated (NYSE:LZB), a global leader in the retail and manufacture of residential furniture, today announced that Matt Baer has been named to the company's Board of Directors, effective January 1, 2025. The appointment will expand the Board to 11 members. Mr. Baer is a seasoned and customer-centric executive who brings extensive retail leadership experience across a variety of disciplines to the Board. He currently serves as Chief Executive Officer of Stitch Fix (NASDAQ:SFIX), the leading online personal styling service, where he is driving a transformation effort. Mr. Baer joined Stitch Fix from Macy's, where he served as the
SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2024 / Quality Industrial Corp. (OTC:QIND) is an Industrial company servicing the Oil & Gas and Utility sectors.The company is pleased to announce that on August 19, 2024, its board of directors approved and ratified the appointment of Bush and Associates CPA ("Bush and Associates") as its independent registered public accounting firm. Bush and Associates will review QIND's consolidated financial statements for the period ending June 30, 2024. They will also audit the company's consolidated financial statements for the fiscal year ending December 31, 2024. Bush and Associates replace Pipara and Co LLP ("Pipara") as QIND's independent auditor.On May
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief Financial Officer, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition. "I am excited to welcome Mr.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut the price target for Lennar Corporation (NYSE:LEN) from $180 to $174. Goldman Sachs analyst Susan Maklari downgraded the stock from Buy to Neutral. Lennar shares gained 0.5% to close at $170.94 on Friday. See how other analysts view this stock. Piper Sandler increased the price target for NVIDIA Corporation (NASDAQ:NVDA) from $120 to $140. Piper Sandler analyst Harsh Kumar maintained an Overweight rating. NVIDIA shares fell 2.6% to close at $117.93 on Friday. See how other analyst
Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT applications, today announced that it has received new orders of over $150,000 for a tier-1 military contractor for its latest cyber-hardened networking solution, the GigaLine 800, which will be deployed on U.S. military bases. This order marks the first major deployment of the GL800, underscoring Actelis' momentum in the military sector following its certification by the National Institute of Standards and Technology (NIST) for FIPS standard, the Joint Interoperability Test Command (JITC), and placement on the U.S. Department of Defense's Approv
Intra-Cellular Therapies (NASDAQ:ITCI) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 4 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 1 0 0 2M Ago 3 2 0 0 0 3M Ago 2 1 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $99.18, a high estimate of $120.00, and a low estimate of $78.00. This current average has increased by 1.96% from the previous
SC 13G - Intra-Cellular Therapies, Inc. (0001567514) (Subject)
SC 13G - ACTELIS NETWORKS INC (0001141284) (Subject)
SC 13G/A - LA-Z-BOY INC (0000057131) (Subject)
8-K - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
10-Q - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
8-K - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Results show robust efficacy and favorable safety and tolerability profile for CAPLYTA BEDMINSTER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced presentations about lumateperone including the results from Phase 3 adjunctive Major Depressive Disorder (MDD) Studies 501 and 502 at Psych Congress held O
FREMONT, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment hybrid networking, recently showcased its GigaLine 900 (GL900) broadband solution at multiple industry events such as WISPAPALOOZA, Broadband Communities West Summit, Connected Britain, and Connected Germany, attracting much interest from providers, integrators and building owners. This attention has underscored the GL900's potential as an ultra-low power, highly cost-effective solution designed to deliver symmetrical Gigabit services, within multi-dwelling units (MDUs), without the need to run new wires or Fiber in the wa
MONROE, Mich., Nov. 05, 2024 (GLOBE NEWSWIRE) -- La-Z-Boy Incorporated (NYSE:LZB) will report its Fiscal 2025 Second Quarter results for the period ended October 26, 2024 after the close of trading on the New York Stock Exchange on Tuesday, November 19, 2024, and will hold its quarterly investor conference call at 8:30 a.m. Eastern Time the following day, Wednesday, November 20, 2024. The conference call will be webcast live with corresponding slides at https://lazboy.gcs-web.com/. The dial-in phone number for the live conference call will be (888) 506-0062 for persons calling from within the U.S. or Canada, and the number for international callers will be (973) 528-0011. The participant
4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
4 - LA-Z-BOY INC (0000057131) (Issuer)
Piper Sandler upgraded Intra-Cellular Therapies from Neutral to Overweight and set a new price target of $92.00 from $68.00 previously
Sidoti downgraded La-Z-Boy from Buy to Neutral and set a new price target of $43.00
Robert W. Baird initiated coverage of Intra-Cellular Therapies with a rating of Outperform and set a new price target of $83.00
MONROE, Mich., Nov. 05, 2024 (GLOBE NEWSWIRE) -- La-Z-Boy Incorporated (NYSE:LZB) will report its Fiscal 2025 Second Quarter results for the period ended October 26, 2024 after the close of trading on the New York Stock Exchange on Tuesday, November 19, 2024, and will hold its quarterly investor conference call at 8:30 a.m. Eastern Time the following day, Wednesday, November 20, 2024. The conference call will be webcast live with corresponding slides at https://lazboy.gcs-web.com/. The dial-in phone number for the live conference call will be (888) 506-0062 for persons calling from within the U.S. or Canada, and the number for international callers will be (973) 528-0011. The participant
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA's strong prescription uptake continues: Q3 2024 CAPLYTA total prescriptions increased 38%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance range raised to $665 to $685 million Following a successful pre-supplemental NDA (sNDA) meeting with the U.S. Food and Drug Administration (FDA), the lumateperone sNDA submission for adjunctive treatment of major depressive disorder (MDD) is anticipated in the fourth quarter of 2024 Patient enrollment ongoing in ITI-1284 Phase 2 studies in generalized anxiety disorder
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2024. To attend the live conference call by phone please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live and arc